《美股业绩》联合健康季度纯利胜预期 维持现财年盈测
美股道指成分股,美国医保巨擘联合健康(UnitedHealth)(UNH.US)公布去年第四季业绩。季度纯利22.12亿美元,按年跌37.5%。每股季度摊薄纯利2.3美元,经调整後为2.52美元,高於市场预期的2.41美元。季度收入654.67亿美元,按年升7.5%。
季度医疗赔付率79.1%,按年跌3.4个百分点,受新冠检测治疗及疫苗成本所影响。公司指盈利受医护服务需求复苏,与及新冠相关治疗优惠成本所拖累。公司维持今年每股经调整盈利预测17.75至18.25美元不变,包括1.8美元新冠相关成本。
联合健康股价昨日(20日)跌0.4%,报350.84美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.